Transcription factor-mediated reprogramming: Epigenetics and therapeutic potential
Date
2015
Authors
Firas, J.
Liu, X.
Lim, S.M.
Polo, J.M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Immunology and Cell Biology, 2015; 93(3):284-289
Statement of Responsibility
Jaber Firas, Xiaodong Liu, Sue Mei Lim, and Jose M Polo
Conference Name
Abstract
Cellular reprogramming refers to the conversion of one cell type into another by altering its epigenetic marks. This can be achieved by three different methods: somatic cell nuclear transfer, cell fusion and transcription factor (TF)-mediated reprogramming. TF-mediated reprogramming can occur through several means, either reverting backwards to a pluripotent state before re-differentiating to a new cell type (otherwise known as induced pluripotency), by transdifferentiating directly into a new cell type (bypassing the intermediate pluripotent stage), or, by using the induced pluripotency pathway without reaching the pluripotent state. The possibility of reprogramming any cell type of interest not only sheds new insights on cellular plasticity, but also provides a novel use of this technology across several platforms, most notably in cellular replacement therapies, disease modelling and drug screening. This review will focus on the different ways of implementing TF-mediated reprogramming, their associated epigenetic changes and its therapeutic potential.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2015 Australasian Society for Immunology Inc. All rights reserved